🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study aims to systematically evaluate the safety and efficacy of adali...
Status
Recruiting
Location
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Start Date
2026-05-22
Trial ID
NCT07595770
Treatments Being Tested
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) ...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2022-12-14
Trial ID
NCT05493501
This is a phase II study to assess the efficacy, safety, and Health Related...
Status
Recruiting
Location
Ryan Nguyen
Start Date
2022-12-28
Trial ID
NCT05613413
Treatments Being Tested
The primary scientific question of interest of this study is whether the co...
Status
Withdrawn
Location
Multiple Locations
Start Date
2023-09-15
Trial ID
NCT05809895
Treatments Being Tested
This phase Ib trials studies the side effects and how well talimogene laher...
Status
Completed
Location
University of California, San Francisco
Start Date
2020-02-05
Trial ID
NCT03554044
This was an open-label, nonrandomized, Phase 1/2 study designed to determin...
Status
Completed
Location
Mayo Clinic Arizona
Start Date
2017-05-02
Trial ID
NCT03085914
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemoth...
Status
Not Yet Recruiting
Location
Tangdu Hospital, Fourth Military Medical University
Start Date
2026-07-10
Trial ID
NCT07678580
A first in human study to evaluate the safety and preliminary antitumor act...
Status
Recruiting
Location
The Angeles Clinic and Research Institute - West Los Angeles Office
Start Date
2025-03-31
Trial ID
NCT06917079
The primary objective of the study is to determine the maximum tolerated do...
Status
Completed
Location
Alabama Oncology
Start Date
2013-03-29
Trial ID
NCT01803282
The primary objective is to determine if mutation load underlies sensitivit...
Status
Terminated
Location
Columbia University
Start Date
2016-05-31
Trial ID
NCT02710396
Treatments Being Tested